title: Comment on: 'Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab'.
authors: Department of Ophthalmology, University of Medicine, Cluj-Napoca, Romania.
authors: D
authors: D
authors: Călugăru
authors: Department of Ophthalmology, University of Medicine, Cluj-Napoca, Romania.
authors: M
authors: M
authors: Călugăru
mesh_terms: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000139:chemically induced*; D000069579:Ranibizumab; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012170:Retinal Vein Occlusion / Q000139:chemically induced*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab